A5047628204- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Drug Transport and Resistance Mechanisms
- RNA modifications and cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Medical Imaging and Pathology Studies
- Cancer-related Molecular Pathways
- Neuroendocrine Tumor Research Advances
- Advanced Breast Cancer Therapies
- Cancer, Hypoxia, and Metabolism
- Medical Imaging Techniques and Applications
- Cell death mechanisms and regulation
- PI3K/AKT/mTOR signaling in cancer
- Cancer-related molecular mechanisms research
Taichung Veterans General Hospital
2016-2025
National Chung Hsing University
2016-2025
I-Shou University
2024
National Defense Medical Center
2024
Tri-Service General Hospital
2024
Zuoying Armed Forces General Hospital
2024
Min-Hwei College of Health Care Management
2024
National Sun Yat-sen University
2024
Tzu Chi University
2024
Quanzhou Normal University
2024
Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved tyrosine kinase inhibitors. Amivantamab, an EGFR-MET bispecific antibody immune cell-directing activity, binds each receptor's extracellular domain, bypassing at the inhibitor binding site.CHRYSALIS is a phase I, open-label, dose-escalation, and dose-expansion study, which included population EGFR Exon20ins NSCLC. The primary end...
Epidermal growth factor receptor exon 20 insertion mutations (EGFRexon20ins) are detected in approximately 2% of patients with non-small cell lung cancer (NSCLC). Due to a lack effective therapy, the prognosis these is typically poor. Sunvozertinib (DZD9008) was designed as an oral, potent, irreversible, and selective EGFR tyrosine kinase inhibitor, showing activity against EGFRexon20ins other mutations. In both lines xenograft models, sunvozertinib shows potent antitumor activity. two...
We report CNS efficacy of first-line osimertinib plus chemotherapy versus monotherapy in patients with epidermal growth factor receptor (
This study aimed to challenge chemoresistance by curcumin (CUR) with drug-selected human lung cancer A549 sublines that continuously proliferate in the present of docetaxel (DOC) and vincristine (VCR). Their sensitivities CUR were measured MTT assay particular intracellular reactive oxygen species (ROS) was detected fluorescence activated cell sorting (FACS) analysis. Apoptosis analyzed Annexin V flow cytometry. Inhibitors RNA interference used examine signaling pathway regulated kinases....
9004 Background: Despite advances in first-line (1L) immunotherapy ± CT, most patients (pts) with aNSCLC experience disease progression, necessitating novel strategies. Dato-DXd is an antibody drug conjugate (ADC) composed of a humanized anti-TROP2 IgG1 monoclonal covalently linked to topoisomerase I inhibitor payload via plasma-stable tetrapeptide-based cleavable linker. had encouraging efficacy and manageable safety heavily pretreated aNSCLC. + yielded greater preclinical activity than...
Lung cancer is considered the number one cause of cancer-related deaths worldwide. Although current treatments initially reduce lung burden, relapse occurs in most cases; major causes mortality are drug resistance and stemness. Recent investigations have provided evidence that shikonin generates various bioactivities related to treatment cancer. We used treat multi-resistant non-small cells (DOC-resistant A549/D16, VCR-resistant A549/V16 cells) defined anti-cancer efficacy shikonin. Our...
Experiments were performed to examine the effect of changes in dietary salt intake on neuronal form constitutive nitric oxide synthase (ncNOS, type I NOS), renin, and angiotensinogen mRNA expression kidney. Three groups Sprague-Dawley rats studied as follows: maintained a 3% Na diet plus 0.45% NaCl drinking fluid for 7 days (high salt), given single injection furosemide (2 mg/kg i.p.) 0.03% (low containing 0.2% (control). was assessed with reverse transcription-polymerase chain reaction...
The present study was undertaken to investigate the mRNA localization of two major kidney-specific Na-K-Cl transport proteins, bumetanide-sensitive cotransporter (NKCC2 in rabbit and BSC1 rat) thiazide-sensitive (TSC). NKCC2 from mouse has been shown exist three isoforms (designated A, B, F) that differ only a 96-bp region. divergent region each cloned rat kidney by polymerase chain reaction (PCR)-based strategy, isoform-specific primers were chosen. RNA cDNA prepared renal cortex medulla...
Recent evidence from several relatively small nested case‐control studies in prospective cohorts shows an association between longer telomere length measured phenotypically peripheral white blood cell (WBC) DNA and increased lung cancer risk. We sought to further explore this relationship by examining a panel of seven telomere‐length associated genetic variants large study 5,457 never‐smoking female Asian cases 4,493 controls using data previously reported genome‐wide study. Using group...
BackgroundEpidermal growth factor receptor (EGFR) mutation status in lung cancer can effectively predict EGFR-tyrosine kinase inhibitor (TKI) efficacy. We evaluated the role of dynamic plasma cell-free DNA EGFR outcome prediction.MethodsAdvanced adenocarcinoma patients were enrolled and prospectively observed for outcomes EGFR-TKI treatment. Peptide nucleic acid–zip acid polymerase chain reaction clamp method was developed to assess mutations matched tumor serial specimens.ResultsA total 72...
Small cell lung carcinoma (SCLC) is uncommon in individuals who have never smoked (never-smokers). The related epidemiologic factors and prognosis remain unclear.To assess the factors, clinical characteristics, outcomes of SCLC never-smokers.A retrospective cohort study was conducted using data from national Taiwan Cancer Registry, which inaugurated 1979 maintains standardized records patients' characteristics information for all with cancer. Patients cytologically or pathologically proven...
Abstract Background In FLAURA2, 1L osi with addition of platinum-pemetrexed chemotherapy (osi + CTx) significantly improved PFS vs alone in pts EGFRm advanced NSCLC. Prior FLAURA analyses showed detected BL plasma to be prognostic and early clearance correlated outcomes. We explored correlation detection, its clearance, FLAURA2 determine potential identify who derive particular benefit from CTx. Methods Treatment-naïve (Ex19del or L858R) NSCLC were randomized CTx 80 mg once daily [QD]...
To provide a frame of reference for studies renal divalent cation and phosphate metabolism, we assessed the cellular localization kidney calcium receptor (RaKCaR), parathyroid hormone-related protein (PTHrP), hormone/ (PTH/PTHrP) mRNA. The used using reverse transcription-polymerase chain reaction (RT-PCR) applied to cDNA prepared from dissected rat nephron segments primary cultures mouse juxtaglomerular granular cells. With species-specific primers, PCR products expected size were obtained...
Chemoresistance in cancer therapy is an unfavorable prognostic factor non-small cell lung (NSCLC). Elevation of intracellular calcium level multidrug resistant (MDR) sublines leads to sensitization MDR death. We demonstrated that a fungal protein from Ganoderma microsporum, GMI, elevates the and reduces growth subline via autophagy apoptosis, regardless p-glycoprotein (P-gp) overexpression, mice xenograft tumors. In addition, we examined roles death A549 by thapsigargin (TG) tunicamycin (TM)...
The main objective of this study was to investigate the relationship among clinical characteristics and frequency T790M mutation in advanced epidermal growth factor receptor (EGFR)‒mutant lung adenocarcinoma patients with acquired resistance after firstline EGFR‒tyrosine kinase inhibitor (TKI) treatment.We enrolled EGFR-mutant stage IIIB-IV patients, who had progressed prior EGFR-TKI therapy, evaluated their rebiopsy EGFR status.A total 205 were for analysis. overall rate 46.3%. rates exon...
Abstract RAGE (receptor for advanced glycation end-product) is thought to be associated with metastasis and poor prognosis of various types cancer. However, constitutively expressed in the normal lung down-regulated cancerous lung, while opposite evidence shows that RAGE-mediated signaling contributes tumorigenesis Therefore, role cancer progression still unclear further investigated. In this study, RAGE-overexpressed stable clones human A549 cells two local adenocarcinoma cell lines CL1-0...
Despite sharing similar tumor biology to other epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) tumors, no targeted therapies have been approved for NSCLC harboring EGFR Exon 20 insertion mutations (Exon20ins). The standard of care remains platinum-based chemotherapy the front-line, with clear subsequent options available. Amivantamab (JNJ-61186372) is a novel, fully human EGFR-MET bispecific antibody immune cell-directing activity that targets activating and...
9008 Background: There are no approved targeted therapies for EGFR exon20 insertion (exon20ins) mutant NSCLC. DZD9008 is a rationally designed selective, irreversible exon20ins inhibitor being studied in two ongoing phase 1/2 studies (NCT03974022 and CTR20192097). Methods: The objectives of the to assess safety, tolerability, pharmacokinetics, preliminary anti-tumor efficacy NSCLC with or HER2 mutations. Both include dose escalation expansion cohorts. Pooled analysis applied define...
The impact of strong Programmed Death-ligand 1 (PD-L1) expression on the clinical outcomes osimertinib in treatment naïve advanced Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC) patients remains uncertain. We enrolled NSCLC who harbored sensitizing EGFR mutation and were treated first-line with between 2017 2021. PD-L1 level was also tested. A total 85 included. objective response rate to 78.9%, disease control being 90.8%. Median Progression-free Survival...
LBA8598 Background: HER2 ( ERBB2) mutations have been reported in approximately 2-4% of patients (pts) with NSCLC, exon 20 insertions being the most common. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor that potently inhibits mutant and EGFR preclinical models. Encouraging objective responses were observed pts NSCLC harboring a HER2-activating mutation treated dose-escalation/backfill part Phase I/II SOHO-01 trial (NCT05099172). More recently FDA has granted Breakthrough...
Pemetrexed is approved for first-line and maintenance treatment of patients with advanced or metastatic non-small-cell lung cancer (NSCLC). The protein kinase Akt/protein B a well-known regulator cell survival which activated by pemetrexed, but its role in pemetrexed-mediated death molecular mechanisms are unclear. This study showed that stimulation pemetrexed induced S-phase arrest apoptosis parallel increase sustained Akt phosphorylation nuclear accumulation the NSCLC A549 line. Inhibition...